Important IMvoke010 trial could shape future research in immunotherapy in locally advanced head and neck cancer – Dana-Farber Cancer Institute

Dana-Farber Cancer Institute shared on X/Twitter:

“Important IMvoke010 trial could shape future research in immunotherapy in locally advanced head and neck cancer after results of 1st phase III study in adjuvant therapy don’t meet event-free survival endpoint. Robert Haddad details findings presented at AACR24. “

Video attached to the link.
Source: Dana-Farber Cancer Institute/X